Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 499-512

  Jaskula Sztul, Renata ^a   Eide, Jacob ^a,d   Tesfazghi, Sara ^a   Dammalapati, Ajitha ^a   Harrison, April D ^a   Yu, Xiao Min ^a   Scheinebeck, Casi ^b   Winston McPherson, Gabrielle ^b   Kupcho, Kevin R ^c   Robers, Matthew B ^c   Hundal, Amrit K ^a   Tang, Weiping ^b   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c PROMEGA CORPORATION   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HISTONE DEACETYLASE INHIBITOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; TUMOR SUPPRESSOR PROTEIN; MOLECULAR LIBRARY; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; THYROID CANCER CELL LINE; THYROID MEDULLARY CARCINOMA; ANIMAL; CARCINOMA; DRUG EFFECTS; GENETICS; IC50; METABOLISM; MOLECULAR LIBRARY; NEUROSECRETION; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE, NUDE; NEUROSECRETORY SYSTEMS; PHENOTYPE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84923365170     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0073     Document Type: Article

References (51)

1. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg 1999;33:1-27.
2. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid 2005;15:511-21.
3. Greenblatt DY, Elson D, Mack E, Chen H. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 2007;30:108-12.
4. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, et al. Routine measurement of serum calcitonin is useful for early detection ofmedullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001;11:73-80.
5. Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998;227:887-95.
6. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 2000;135:895-901.
7. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
8. Wells SA, Gosnell JE, Gagel RF, Moley J, P fi ster D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
9. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist 2013;18:1093-100.
10. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010;39:775-83.
11. Chen H, Biel MA, Borges MW, Thiagalingam A, Nelkin BD, Baylin SB, et al. Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 1997;8:677-86.
12. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003;134:866-71; discussion 71-3.
13. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006;281:39819-30.
14. Kameda Y, Nishimaki T, Miura M, Jiang SX, Guillemot F. Mash1 regulates the development of C cells in mouse thyroid glands. Dev Dyn 2007;236:262-70.
15. Ball DW. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 2004;204:159-69.
16. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
17. Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, et al. Notch signaling induces rapid degradation of achaetescute homolog 1. Mol Cell Biol 2002;22:3129-39.
18. Jaskula-Sztul R, Pisarnturakit P, Landowski M, Chen H, Kunnimalaiyaan M. Expression of the active Notch1 decreases MTC tumor growth in vivo. J Surg Res 2011;171:23-7.
19. Maillard I, Pear WS. Notch and cancer: best to avoid the ups and downs. Cancer Cell 2003;3:203-5.
20. Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci 2005;8:709-15.
21. Kopan R. Notch signaling. Cold Spring Harb Perspect Biol 2012;4:pii: a011213.
22. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activationwith turnover. Mol Cell 2004;16:509-20.
23. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
24. Tang W, Luo T, Greenberg EF, Bradner JE, Schreiber SL. Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett 2011;21:2601-5.
25. Tesfazghi S, Eide J, Dammalapati A, Korlesky C, Wyche TP, Bugni TS, et al. Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line. Cancer Medicine 2013;2:734-43.
26. Halley F, Reinshagen J, Ellinger B, Wolf M, Niles AL, Evans NJ, et al. A bioluminogenic HDAC activity assay: validation and screening. J Biomol Screen 2011;16:1227-35.
27. Yu XM, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M, Chen H. Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther 2013;12:1276-87.
28. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Lagerholm S, Chen H. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G245-54.
29. Vaccaro A, Chen H, Kunnimalaiyaan M. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograftmodel of humanmedullary thyroid cancer. Anticancer Drugs 2006;17:849-53.
30. Cawthorne C, Swindell R, Stratford IJ, Dive C, Welman A. Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. J Biomol Tech 2007;18:120-3.
31. Wang W, Campos AH, Prince CZ, Mou Y, Pollman MJ. Coordinate Notch3-hairy-related transcription factor pathway regulation in response to arterial injury. Mediator role of platelet-derived growth factor and ERK. J Biol Chem 2002;277:23165-71.
32. Shimizu K, Chiba S, Saito T, Kumano K, Hamada Y, Hirai H. Functional diversity among Notch1, Notch2, and Notch3 receptors. Biochem Biophys Res Commun 2002;291:775-9.
33. Cook M, Yu XM, Chen H. Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res 2010;2:119-25.
34. Pinchot SN, Jaskula-Sztul R, Ning L, Peters NR, Cook MR, Kunnimalaiyaan M, et al. Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer 2011;117:1386-98.
35. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61.
36. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 2010;29:201-13.
37. Natarajan S, Li Y, Miller EE, Shih DJ, Taylor MD, Stearns TM, et al. Notch1- induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. Cancer Res 2013;73:5381-90.
38. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010;70:1469-78.
39. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 2012;131:2668-77.
40. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G636-42.
41. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61:3200-5.
42. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009;16:55-66.
43. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000;92:1355-7.
44. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocksmammary gland development and inducesmammary tumors. Am J Pathol 2006;168:973-90.
45. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008;68:1881-8.
46. Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue sitespecific manner. Cancer Res 2011;71:1115-25.
47. Sera fin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol 2011;224:448-60.
48. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A, et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. Embo J 2000;19:3337-48.
49. Kadesch T. Notch signaling: the demise of elegant simplicity. Curr Opin Genet Dev 2004;14:506-12.
50. Shepet K, Alhefdhi A, Lai N, Mazeh H, Sippel R, Chen H. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol 2013;20:1451-5.
51. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 2013;24:499-511.